Enabling Formulation Approaches: Considerations to advance solid dispersions into late stage development
Posted on April 17, 2013
By: Keith Horspool, Vice President Pharmaceutical Development; Chandan Bhugra, Principal Scientist; Anjali Agrawal, Principal Scientist; Sid Mujumdar, Was Principal Scientist at Boehringer Ingelheim Pharmaceuticals, Now Principal Scientist – Formulation Expert at Novartis; Dongmei Qiang, Principal Scientist
Boehringer Ingelheim Pharmaceuticals
Introduction Most drug candidates in the pharmaceutical development pipeline are characterised by poor aqueous solubility. In an earlier publication, we outlined some factors that can be considered to set up an appropriate strategy early on, for developing bioavailable formulations of such poorly s...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
Amorphous Solid Dispersions (ASD), bioavailability, Boehringer Ingelheim, formulation, Hot melt extrusion, solid dispersions, solubility, Spray dried dispersions
Related Product Videos
Related Products
Your Spray Drying solution for solid dispersions - BUCHIAPI development and manufacturing for the pharmaceutical industry - Hovione
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
